Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02192099 · ClinicalTrials.gov registry record · Phase 2
Open Label Extension for GLYX13-C-202, NCT01684163
A Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02192099 is a Phase 2 study that was terminated before completion, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 61 participants.
The verdict
NCT02192099, a Phase 2 study, was terminated before completion, sponsored by Naurex, Inc, an affiliate of Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
Interventions
- DRUG Rapastinel (225 mg/450 mg IV administration)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-09-08 |
| Est. Completion | 2018-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02192099
The ClinicalTrials.gov registry entry for NCT02192099 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rapastinel (225 mg/450 mg IV administration) is the first listed.
NCT02192099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02192099 about?
NCT02192099 is a clinical study titled "Open Label Extension for GLYX13-C-202, NCT01684163". Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
What is the current status of trial NCT02192099?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2014-09-08. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT02192099?
The interventions under investigation include: Rapastinel (225 mg/450 mg IV administration) (DRUG).
Who is sponsoring clinical trial NCT02192099?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.